AG˹ٷ

STOCK TITAN

[Form 4] Triumph Financial, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 overview: Director Laura Berner of Bolt Biotherapeutics (BOLT) reported a single equity-based transaction dated May 27 2025. She received a non-qualified stock option for 1,100 common shares at an exercise price of $6.40 per share. All figures give effect to the 1-for-20 reverse stock split that the company executed on June 6 2025.

Key terms of the grant:

  • Vesting: Options vest on the earlier of May 27 2026 or the day immediately prior to the next annual meeting, subject to continued service.
  • Change-in-control: The award vests in full upon a change-in-control event.
  • Expiration: May 26 2035 (10-year life).

No shares were purchased or sold; the filing reflects compensation-related option issuance. Post-grant, Berner beneficially owns 1,100 derivative securities and no disclosed non-derivative common shares.

Corporate context: The recent reverse split consolidated each 20 common shares into one, reducing the share count and proportionally increasing exercise prices. Prior to the split, the grant was for 22,000 shares at $0.32 per share. The filing provides no additional financial or operational data.

Panoramica del Modulo 4: La direttrice Laura Berner di Bolt Biotherapeutics (BOLT) ha riportato una singola transazione basata su azioni datata 27 maggio 2025. Ha ricevuto un opzione su azioni non qualificate per 1.100 azioni ordinarie con un prezzo di esercizio di 6,40 $ per azione. Tutte le cifre tengono conto del raggruppamento azionario inverso 1-per-20 eseguito dalla società il 6 giugno 2025.

Termini chiave della concessione:

  • Vestizione: Le opzioni maturano al primo tra il 27 maggio 2026 o il giorno precedente alla prossima assemblea annuale, subordinatamente alla continuazione del servizio.
  • Cambio di controllo: Il premio matura completamente in caso di evento di cambio di controllo.
  • Scadenza: 26 maggio 2035 (durata di 10 anni).

Non sono state acquistate o vendute azioni; la dichiarazione riflette un'emissione di opzioni legata alla compensazione. Dopo la concessione, Berner detiene beneficiariamente 1.100 titoli derivati e nessuna azione ordinaria non derivata dichiarata.

Contesto aziendale: Il recente raggruppamento inverso ha consolidato ogni 20 azioni ordinarie in una, riducendo il numero di azioni e aumentando proporzionalmente i prezzi di esercizio. Prima del raggruppamento, la concessione riguardava 22.000 azioni a 0,32 $ per azione. La dichiarazione non fornisce ulteriori dati finanziari o operativi.

Resumen del Formulario 4: La directora Laura Berner de Bolt Biotherapeutics (BOLT) reportó una única transacción basada en acciones con fecha 27 de mayo de 2025. Recibió una opción sobre acciones no calificadas para 1,100 acciones ordinarias con un precio de ejercicio de $6.40 por acción. Todas las cifras reflejan el split inverso 1 por 20 que la empresa ejecutó el 6 de junio de 2025.

Términos clave de la concesión:

  • DzԲDZ岹ó: Las opciones se consolidan en la fecha que ocurra primero entre el 27 de mayo de 2026 o el día previo a la próxima junta anual, sujeto a la continuidad del servicio.
  • Cambio de control: El premio se consolida completamente en caso de un evento de cambio de control.
  • Vencimiento: 26 de mayo de 2035 (vida útil de 10 años).

No se compraron ni vendieron acciones; la presentación refleja una emisión de opciones relacionada con compensación. Tras la concesión, Berner posee beneficiosamente 1,100 valores derivados y ninguna acción ordinaria no derivada divulgada.

Contexto corporativo: El reciente split inverso consolidó cada 20 acciones ordinarias en una, reduciendo el número de acciones y aumentando proporcionalmente los precios de ejercicio. Antes del split, la concesión era para 22,000 acciones a $0.32 por acción. La presentación no proporciona datos financieros u operativos adicionales.

Form 4 개요: Bolt Biotherapeutics(BOLT)� 이사 Laura Berner� 2025� 5� 27�$6.40� 행사가격으� 1,100� 보통주에 대� 비자� 스톡 옵션� 받았습니�. 모든 수치� 회사가 2025� 6� 6�� 실행� 1대 20 역병�� 반영합니�.

부� 주요 조건:

  • 베스�: 옵션은 2026� 5� 27� 또는 다음 연례 총회 전날 � 빠른 날짜� 베스팅되�, 계속 근무 조건� 적용됩니�.
  • 지배구� 변� �: 지배구� 변� 이벤� 발생 � 전액 베스팅됩니다.
  • 만료: 2035� 5� 26� (10� 만기).

주식 매매� 없었으며, 제출 서류� 보상 관� 옵션 발행� 반영합니�. 부� � Berner� 1,100개의 파생 증권� 실질적으� 보유하며, 공개� 비파� 보통주는 없습니다.

기업 배경: 최근 역병합으� 보통� 20주가 1주로 통합되어 주식 수가 줄고 행사가격이 비례하여 상승했습니다. 병합 전에� 22,000주에 주당 $0.32� 조건이었습니�. 제출 서류에는 추가 재무 또는 운영 데이터가 포함되어 있지 않습니다.

Vue d'ensemble du formulaire 4 : La directrice Laura Berner de Bolt Biotherapeutics (BOLT) a déclaré une seule transaction basée sur des actions datée du 27 mai 2025. Elle a reçu une option d'achat d'actions non qualifiée pour 1 100 actions ordinaires à un prix d'exercice de 6,40 $ par action. Tous les chiffres tiennent compte du split inversé 1 pour 20 effectué par la société le 6 juin 2025.

Principaux termes de l'attribution :

  • Vesting : Les options deviennent acquises à la première date entre le 27 mai 2026 ou la veille de la prochaine assemblée générale annuelle, sous réserve de la poursuite du service.
  • Changement de contrôle : L'attribution devient entièrement acquise en cas d'événement de changement de contrôle.
  • Expiration : 26 mai 2035 (durée de 10 ans).

Aucune action n'a été achetée ou vendue ; le dépôt reflète une émission d'options liée à la rémunération. Après l'attribution, Berner détient effectivement 1 100 titres dérivés et aucune action ordinaire non dérivée divulguée.

Contexte de l'entreprise : Le récent split inversé a consolidé chaque 20 actions ordinaires en une seule, réduisant le nombre d'actions et augmentant proportionnellement les prix d'exercice. Avant le split, l'attribution portait sur 22 000 actions à 0,32 $ par action. Le dépôt ne fournit pas de données financières ou opérationnelles supplémentaires.

Überblick Formular 4: Direktorin Laura Berner von Bolt Biotherapeutics (BOLT) meldete eine einzelne aktienbasierte Transaktion vom 27. Mai 2025. Sie erhielt eine nicht qualifizierte Aktienoption über 1.100 Stammaktien zu einem Ausübungspreis von 6,40 $ pro Aktie. Alle Zahlen berücksichtigen den 1-zu-20 Reverse-Split, den das Unternehmen am 6. Juni 2025 durchgeführt hat.

Wesentliche Bedingungen der Gewährung:

  • Vesting: Die Optionen werden am früheren Datum von 27. Mai 2026 oder dem Tag vor der nächsten Hauptversammlung fällig, vorbehaltlich fortgesetzter Dienstzeit.
  • Kontrollwechsel: Die Auszeichnung wird bei einem Kontrollwechselereignis vollständig fällig.
  • Ablauf: 26. Mai 2035 (10 Jahre Laufzeit).

Es wurden keine Aktien gekauft oder verkauft; die Meldung spiegelt eine vergütungsbezogene Optionsausgabe wider. Nach der Gewährung hält Berner wirtschaftlich 1.100 derivative Wertpapiere und keine offengelegten nicht-derivativen Stammaktien.

Unternehmenskontext: Der jüngste Reverse-Split fasste jeweils 20 Stammaktien zu einer zusammen, wodurch die Anzahl der Aktien reduziert und die Ausübungspreise proportional erhöht wurden. Vor dem Split betrug die Gewährung 22.000 Aktien zu je 0,32 $. Die Meldung enthält keine weiteren finanziellen oder operativen Daten.

Positive
  • Director incentive alignment: Granting stock options ties board compensation to future share performance.
  • Clear vesting schedule: One-year cliff and change-in-control acceleration provide transparent terms for investors.
Negative
  • Reverse stock split highlighted: A 1-for-20 consolidation suggests prior share-price pressure, though no explicit rationale is provided.

Insights

TL;DR: Routine board option grant; minor impact.

The Form 4 discloses a standard annual equity award to an outside director. Post-split sizing�1,100 options—appears immaterial versus Bolt Biotherapeutics� public float. The 10-year term and single-year cliff vest align with typical small-cap governance practices, while the change-in-control acceleration is common in biotech. Because no shares were bought or sold, the filing does not imply insider sentiment toward the current market price. Investors should view the disclosure as routine compensation rather than a signal.

TL;DR: Reverse split noted; no transactional signal.

The grant references Bolt’s 1-for-20 reverse split executed on June 6 2025, confirming the corporate action is now effective. Reverse splits often target listing-price compliance, but the form supplies no context beyond execution. The option pricing and share count were mechanically adjusted, maintaining economic equivalence. Overall, the disclosure is informational, not indicative of forthcoming capital raises or strategic shifts.

Panoramica del Modulo 4: La direttrice Laura Berner di Bolt Biotherapeutics (BOLT) ha riportato una singola transazione basata su azioni datata 27 maggio 2025. Ha ricevuto un opzione su azioni non qualificate per 1.100 azioni ordinarie con un prezzo di esercizio di 6,40 $ per azione. Tutte le cifre tengono conto del raggruppamento azionario inverso 1-per-20 eseguito dalla società il 6 giugno 2025.

Termini chiave della concessione:

  • Vestizione: Le opzioni maturano al primo tra il 27 maggio 2026 o il giorno precedente alla prossima assemblea annuale, subordinatamente alla continuazione del servizio.
  • Cambio di controllo: Il premio matura completamente in caso di evento di cambio di controllo.
  • Scadenza: 26 maggio 2035 (durata di 10 anni).

Non sono state acquistate o vendute azioni; la dichiarazione riflette un'emissione di opzioni legata alla compensazione. Dopo la concessione, Berner detiene beneficiariamente 1.100 titoli derivati e nessuna azione ordinaria non derivata dichiarata.

Contesto aziendale: Il recente raggruppamento inverso ha consolidato ogni 20 azioni ordinarie in una, riducendo il numero di azioni e aumentando proporzionalmente i prezzi di esercizio. Prima del raggruppamento, la concessione riguardava 22.000 azioni a 0,32 $ per azione. La dichiarazione non fornisce ulteriori dati finanziari o operativi.

Resumen del Formulario 4: La directora Laura Berner de Bolt Biotherapeutics (BOLT) reportó una única transacción basada en acciones con fecha 27 de mayo de 2025. Recibió una opción sobre acciones no calificadas para 1,100 acciones ordinarias con un precio de ejercicio de $6.40 por acción. Todas las cifras reflejan el split inverso 1 por 20 que la empresa ejecutó el 6 de junio de 2025.

Términos clave de la concesión:

  • DzԲDZ岹ó: Las opciones se consolidan en la fecha que ocurra primero entre el 27 de mayo de 2026 o el día previo a la próxima junta anual, sujeto a la continuidad del servicio.
  • Cambio de control: El premio se consolida completamente en caso de un evento de cambio de control.
  • Vencimiento: 26 de mayo de 2035 (vida útil de 10 años).

No se compraron ni vendieron acciones; la presentación refleja una emisión de opciones relacionada con compensación. Tras la concesión, Berner posee beneficiosamente 1,100 valores derivados y ninguna acción ordinaria no derivada divulgada.

Contexto corporativo: El reciente split inverso consolidó cada 20 acciones ordinarias en una, reduciendo el número de acciones y aumentando proporcionalmente los precios de ejercicio. Antes del split, la concesión era para 22,000 acciones a $0.32 por acción. La presentación no proporciona datos financieros u operativos adicionales.

Form 4 개요: Bolt Biotherapeutics(BOLT)� 이사 Laura Berner� 2025� 5� 27�$6.40� 행사가격으� 1,100� 보통주에 대� 비자� 스톡 옵션� 받았습니�. 모든 수치� 회사가 2025� 6� 6�� 실행� 1대 20 역병�� 반영합니�.

부� 주요 조건:

  • 베스�: 옵션은 2026� 5� 27� 또는 다음 연례 총회 전날 � 빠른 날짜� 베스팅되�, 계속 근무 조건� 적용됩니�.
  • 지배구� 변� �: 지배구� 변� 이벤� 발생 � 전액 베스팅됩니다.
  • 만료: 2035� 5� 26� (10� 만기).

주식 매매� 없었으며, 제출 서류� 보상 관� 옵션 발행� 반영합니�. 부� � Berner� 1,100개의 파생 증권� 실질적으� 보유하며, 공개� 비파� 보통주는 없습니다.

기업 배경: 최근 역병합으� 보통� 20주가 1주로 통합되어 주식 수가 줄고 행사가격이 비례하여 상승했습니다. 병합 전에� 22,000주에 주당 $0.32� 조건이었습니�. 제출 서류에는 추가 재무 또는 운영 데이터가 포함되어 있지 않습니다.

Vue d'ensemble du formulaire 4 : La directrice Laura Berner de Bolt Biotherapeutics (BOLT) a déclaré une seule transaction basée sur des actions datée du 27 mai 2025. Elle a reçu une option d'achat d'actions non qualifiée pour 1 100 actions ordinaires à un prix d'exercice de 6,40 $ par action. Tous les chiffres tiennent compte du split inversé 1 pour 20 effectué par la société le 6 juin 2025.

Principaux termes de l'attribution :

  • Vesting : Les options deviennent acquises à la première date entre le 27 mai 2026 ou la veille de la prochaine assemblée générale annuelle, sous réserve de la poursuite du service.
  • Changement de contrôle : L'attribution devient entièrement acquise en cas d'événement de changement de contrôle.
  • Expiration : 26 mai 2035 (durée de 10 ans).

Aucune action n'a été achetée ou vendue ; le dépôt reflète une émission d'options liée à la rémunération. Après l'attribution, Berner détient effectivement 1 100 titres dérivés et aucune action ordinaire non dérivée divulguée.

Contexte de l'entreprise : Le récent split inversé a consolidé chaque 20 actions ordinaires en une seule, réduisant le nombre d'actions et augmentant proportionnellement les prix d'exercice. Avant le split, l'attribution portait sur 22 000 actions à 0,32 $ par action. Le dépôt ne fournit pas de données financières ou opérationnelles supplémentaires.

Überblick Formular 4: Direktorin Laura Berner von Bolt Biotherapeutics (BOLT) meldete eine einzelne aktienbasierte Transaktion vom 27. Mai 2025. Sie erhielt eine nicht qualifizierte Aktienoption über 1.100 Stammaktien zu einem Ausübungspreis von 6,40 $ pro Aktie. Alle Zahlen berücksichtigen den 1-zu-20 Reverse-Split, den das Unternehmen am 6. Juni 2025 durchgeführt hat.

Wesentliche Bedingungen der Gewährung:

  • Vesting: Die Optionen werden am früheren Datum von 27. Mai 2026 oder dem Tag vor der nächsten Hauptversammlung fällig, vorbehaltlich fortgesetzter Dienstzeit.
  • Kontrollwechsel: Die Auszeichnung wird bei einem Kontrollwechselereignis vollständig fällig.
  • Ablauf: 26. Mai 2035 (10 Jahre Laufzeit).

Es wurden keine Aktien gekauft oder verkauft; die Meldung spiegelt eine vergütungsbezogene Optionsausgabe wider. Nach der Gewährung hält Berner wirtschaftlich 1.100 derivative Wertpapiere und keine offengelegten nicht-derivativen Stammaktien.

Unternehmenskontext: Der jüngste Reverse-Split fasste jeweils 20 Stammaktien zu einer zusammen, wodurch die Anzahl der Aktien reduziert und die Ausübungspreise proportional erhöht wurden. Vor dem Split betrug die Gewährung 22.000 Aktien zu je 0,32 $. Die Meldung enthält keine weiteren finanziellen oder operativen Daten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Miller Maribess L

(Last) (First) (Middle)
12700 PARK CENTRAL DRIVE
SUITE 1700

(Street)
DALLAS TX 75251

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Triumph Financial, Inc. [ TFIN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 A 613(1) A $0(1) 19,699 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of Common Stock of Issuer granted to the reporting person under Issuer's 2014 Omnibus Incentive Plan. All of such shares were fully vested as of the date of grant.
Remarks:
/s/ Adam D. Nelson, Attorney-in-fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Bolt Biotherapeutics (BOLT) disclose in this Form 4?

One director received 1,100 stock options at a $6.40 strike price; no shares were bought or sold.

When will the options granted to Director Laura Berner vest?

They vest on May 27 2026 or immediately before the next annual shareholder meeting, whichever comes first.

What is the expiration date of the reported stock options?

The options expire on May 26 2035.

How did Bolt’s recent 1-for-20 reverse split affect the option grant?

Share and price totals were adjusted from 22,000 options at $0.32 to 1,100 options at $6.40 post-split.

Did the filing indicate any insider buying or selling of common shares?

No. The Form 4 only records an option award; no common shares were transacted.
Triumph Financial Inc

NASDAQ:TFIN

TFIN Rankings

TFIN Latest News

TFIN Latest SEC Filings

TFIN Stock Data

1.49B
22.36M
5.5%
93.76%
7.32%
Banks - Regional
State Commercial Banks
United States
DALLAS